IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Brad C. Dunlap who wrote (505)	3/20/1997 8:23:00 PM
From: Pseudo Biologist	of 1762

Brad, you are correct about the IDEC/Genentech/Xoma deal. See xoma.com for the press release. It appears that Xoma has a patent specific for anti-CD20 chimeric Abs, which is what C2B8 is. Regarding the humanized Ab, the prospectus for IDEC's 96 offering lists just an anti-gp39 (after a very brief scan of the document it is not clear from what virus this glycoprotein, gp, comes from) Its status was listed as "lead compound identified" and Esai Ltd is mentioned as corporate partner for this project. Max

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next